Spray-dried pharmaceutical compositions comprising active agent nanoparticles
AssigneeBesins Healthcare Luxembourg Sarl
InventorsMaynard Emanuel Lichty, Garry T. Gwozdz
Life of this patent
Estimating the term…
Loading patent…
AssigneeBesins Healthcare Luxembourg Sarl
InventorsMaynard Emanuel Lichty, Garry T. Gwozdz
Estimating the term…
Provided herein are dry pharmaceutical compositions for transmucosal delivery, comprising spray-dried particles that include pharmaceutically active agent nanoparticles, a binder, and a pharmaceutically acceptable carrier, where the active agent nanoparticles have an average particle size diameter prior to spray-drying of less than about 1 μm, and wherein up to 10% of the spray-dried particles have a particle size of less than 10 μm; at least 50% of the spray-dried particles have a particle size of at least about 15 μm; and at least 90% of the spray-dried particles have a particle size of up to about 55 μm. Also provided are methods for making such pharmaceutical compositions and therapeutic methods comprising transmucosally administering the compositions, such as intranasally or intravaginally.
1-20. (canceled)
A dry powder pharmaceutical composition for transmucosal administration, comprising spray-dried particles consisting of (i) pharmaceutically active agent nanoparticles consisting of pharmaceutically active agent and, optionally, a milling aid, (ii) binder, (iii) a water-insoluble pharmaceutically acceptable carrier selected from water insoluble celluloses and water-insoluble starches, and, optionally, (iv) a milling aid, wherein:
The method of claim 38, wherein the water-insoluble carrier is microcrystalline cellulose (MCC), and the binder is selected from the group consisting of hydroxypropyl methyl cellulose (HPMC) and sodium carboxymethylcellulose (NaCMC).
Dependencies are inferred from the claim text.